Search

Cosibelimab

On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

Damoctocog alfa pegol

[L4576,A38909] This product has been engineered by Bayer[L4576] and a biological license application has been filed with the FDA in August 2017 and FDA approved in August 2018.[F1609]

Uprosertib

Uprosertib has been used in trials studying the treatment of Cancer, Melanoma, Solid Tumours, Cervical Cancer, and HER2/Neu Negative, among others.

TAS-108

Taselisib

Taselisib has been used in trials studying the treatment and basic science of LYMPHOMA, Breast Cancer, Ovarian Cancer, Solid Neoplasm, and HER2/Neu Negative, among others.

N-acetyl-alpha-neuraminic acid

(From Dorland, 28th ed, p1518)

Acellular nerve allograft

Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral

Vilazodone

Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].

Tenocyclidine

Tenocyclidine (TCP, thienyl cyclohexylpiperidine) is a dissociative anesthetic drug with stimulant and hallucinogenic effects. It is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.

Suvecaltamide

Suvecaltamide is under investigation in clinical trial NCT05122650 (A Study to Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)).